Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Cherrington AL, Tripputi MT, Younes N, Herman WH, Katona A, Groessl EJ, Craig J, Gonzalez JS, Garg R, Casula S, Kuo S, Florez HJ

Diabetes care1 Apr 2024Cited by 4 (Europe PMC)

PMID38190625PMCIDPMC10973906DOI10.2337/dc23-1648PepBankPUB-38190625

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, SF-36 PCS scores improved with liraglutide versus the other groups at year 1 only.
In plain wordsIn adults with type 2 diabetes on metformin, physical quality-of-life scores improved more with liraglutide than with the other drugs at year 1.
Peptide
Liraglutide
Outcome
IncreaseSF-36 physical component summary (PCS) at year 1
Study
n: not reported in source
Comparator
Glargine, glimepiride and sitagliptin
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
PCS scores improved with liraglutide versus other groups at year 1 only.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin.
Report a problemFND-3819062503
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, the PCS improvement with liraglutide versus the other medications was no longer significant at years 2 and 3.
In plain wordsIn adults with type 2 diabetes on metformin, the physical quality-of-life advantage of liraglutide over the other drugs was gone by years 2 and 3.
Peptide
Liraglutide
Outcome
No significant changeSF-36 PCS at years 2 and 3
Study
n: not reported in source
Comparator
Glargine, glimepiride and sitagliptin
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
showed improvement in the SF-36 PCS in comparisons with the other medications at 1 year, which was no longer significant at years 2 and 3.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin.
Report a problemFND-3819062504
03HumanRandomized controlled trialMechanism
In adults with type 2 diabetes on metformin, greater weight loss during year 1 explained half of the PCS improvement with liraglutide versus glargine and glimepiride.
In plain wordsIn adults with type 2 diabetes on metformin, weight loss explained about half of the physical quality-of-life gain with liraglutide compared with glargine and glimepiride.
Peptide
Liraglutide
Outcome
Not applicableWeight loss as mediator of PCS improvement with liraglutide
Study
n: not reported in source
Comparator
Glargine and glimepiride
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Greater weight loss during year 1 explained half the improvement in PCS scores with liraglutide versus glargine and glimepiride.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin.
Report a problemFND-3819062505
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide participants in the upper tertile of baseline BMI showed the greatest improvement in PCS scores at year 1.
In plain wordsIn adults with type 2 diabetes on metformin, liraglutide users with the highest starting BMI improved most in physical quality-of-life scores at year 1.
Peptide
Liraglutide
Outcome
IncreasePCS improvement by baseline BMI tertile at year 1
Study
n: not reported in source
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide participants in the upper tertile of baseline BMI showed the greatest improvement in PCS scores at year 1.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin.
Report a problemFND-3819062506

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, none of the four randomised medications (glargine, glimepiride, liraglutide, sitagliptin) worsened health-related quality of life.
In plain wordsIn adults with type 2 diabetes on metformin, none of the four added drugs worsened quality of life.
Peptide
Liraglutide
Outcome
No significant changeHealth-related quality of life, all four medications
Study
n = 5,047
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
None of the medications worsened HRQoL.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3819062501
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, there were no differences in QWB-SA or MCS between the four treatment groups at any time point.
In plain wordsIn adults with type 2 diabetes on metformin, the four added drugs did not differ in these quality-of-life scores at any time point.
Peptide
Liraglutide
Outcome
No significant changeQWB-SA and MCS by treatment group
Study
n: not reported in source
Outcome group
Exercise and physical function · Whole body
Source sentences
Summary
There were no differences in QWB-SA or MCS by treatment group at any time point.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 5,047 participants, baseline mean age 57 years, with <10 years T2D duration and glycated hemoglobin level 6.8-8.5% and taking metformin monotherapy, were randomly assigned to glargine, glimepiride, liraglutide, or sitagliptin.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3819062502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01794143

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

GRADE Study Groupn = 7,850May 2013 to 30 Apr 2021

Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications

Trial page ClinicalTrials.govUpdated 10 Feb 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.